Foundayo Safety Guide

Foundayo side effects: what the data actually shows

By Iacob Pastina · Independent Researcher & Publisher · Updated August 14, 2026

The most common Foundayo side effects are gastrointestinal: nausea (35%), diarrhea (25%), vomiting (24%), and constipation (24%). 98% of GI side effects in the ATTAIN-1 trial were mild to moderate and improved over time. Foundayo (orforglipron) is Eli Lilly's first oral GLP-1 receptor agonist, FDA-approved April 1, 2026. Unlike Rybelsus (oral semaglutide), Foundayo has no fasting requirement and no food restrictions. All percentages below come from the FDA-approved Foundayo prescribing information.

Call your doctor or 911 immediately if you experience:

• Severe upper abdominal pain radiating to the back (possible pancreatitis, call 911)
• Difficulty breathing, throat swelling, or widespread hives (call 911)
• Inability to keep fluids down for 24+ hours (kidney-injury risk, call your provider or ER)
• Sharp upper-right pain after fatty meals with fever or jaundice (gallbladder, provider call)
• New or worsening suicidal thoughts (call your provider AND 988)

Report any serious adverse event to FDA MedWatch.

Common side effects: rates from the Foundayo label

Source: FDA-approved prescribing information for Foundayo. Some trial publications report a 36 mg orforglipron capsule; that trial formulation is described as bioequivalent to the commercial 17.2 mg tablet and is not a patient dosing instruction.

Side effect	Rate	Severity	When it peaks
Nausea	35%	Mild to moderate	Weeks 4-12 (during dose escalation)
Diarrhea	25%	Mild to moderate	Weeks 1-8
Vomiting	24%	Mild to moderate	Weeks 4-12
Constipation	24%	Mild	Weeks 4-16
Abdominal pain	~14%	Mild cramping (severe pain is a red flag)	Weeks 1-8
Headache	~10%	Mild	Weeks 1-4
Decreased appetite	Common	Often perceived as benefit	Weeks 2-12
Fatigue	~8%	Mild	Weeks 1-8
Hair loss (telogen effluvium)	5.4%	Cosmetic, temporary	Months 3-6 (related to rapid weight loss, not the drug directly)

What's different about Foundayo vs other GLP-1s

• Oral pill, not injection. No needles, no pen device, no refrigeration.
• No fasting requirement. Take it any time, with or without food. Unlike Rybelsus (oral semaglutide), which requires 30 min fasted with only 4oz of water.
• Once-daily dosing. Daily pill instead of weekly injection. Some users prefer the routine; some find it harder to remember.
• Lower weight loss than injectables. 12.4% in trials vs Wegovy's 14.9% and Zepbound's 20.9%. Tradeoff for the convenience of an oral pill.
• Self-pay is dose-dependent: $149/mo at 0.8 mg; $199/mo at 2.5 mg; $299/mo at 5.5 mg or 9 mg; $299/mo at 14.5 mg or 17.2 mg when refilled within 45 days, otherwise $349/mo. Confirm the prescribed strength and refill timing at checkout.

What to expect, week by week

The approved tablet sequence is 0.8 → 2.5 → 5.5 → 9 → 14.5 → 17.2 mg. The label requires at least 30 days at each strength before any prescriber-directed increase. Do not use older trial-capsule strengths as patient dosing instructions.

Step 1 (0.8 mg; at least 30 days)

What's typical: This is the labeled starting strength. Gastrointestinal symptoms can begin during treatment initiation; do not advance early or change the dose on your own.

Red flags: Persistent vomiting, severe abdominal pain, allergic reaction symptoms.

Step 2 (2.5 mg; at least 30 days)

What's typical: A prescriber may increase to this strength only after at least 30 days at 0.8 mg. Review hydration, food intake, and tolerability before any increase.

Red flags: Inability to keep fluids down for 24+ hours, severe upper abdominal pain radiating to back, fever.

Step 3 (5.5 mg; at least 30 days)

What's typical: GI symptoms may recur after an increase. A slower schedule or holding the current strength is a prescriber decision based on response and tolerability.

Red flags: Worsening rather than improving symptoms; contact your prescriber before considering another dose increase.

Step 4 (9 mg; at least 30 days)

What's typical: Continue only as prescribed. Dose response and side effects vary, so the next increase is not automatic even after 30 days.

Red flags: New or worsening upper-right abdominal pain (gallbladder), severe fatigue with low urine output (kidney).

Step 5 (14.5 mg; at least 30 days)

What's typical: This is one of the higher labeled strengths. Review persistent nausea, vomiting, constipation, and hydration with your prescriber before any further increase.

Red flags: Any severe or persistent GI symptom, dehydration, jaundice, or new severe abdominal pain warrants prompt clinical review.

Step 6 (17.2 mg; maintenance strength)

What's typical: This is the highest labeled strength. It is reached only after at least 30 days at every preceding step and only when directed by the prescriber.

Red flags: Any new symptom that emerges months into treatment warrants a provider call, late-onset pancreatitis and gallbladder issues do occur.

Management protocols for the most common side effects

Nausea (35% of patients)

• Eat smaller, more frequent meals (5-6 small instead of 3 large)
• Avoid fatty, fried, spicy, or highly aromatic foods during dose escalation
• Stay hydrated with small sips throughout the day; ginger or peppermint tea helps many users
• Take Foundayo at the same time each day; if nausea is worst in the morning, try evening dosing
• If nausea is intolerable, contact your prescriber before the next increase; the label requires at least 30 days at each strength, and a longer hold may be appropriate

Diarrhea (25%) and Vomiting (24%)

• Maintain hydration as the priority, water plus electrolytes (sports drinks, oral rehydration salts)
• BRAT diet (bananas, rice, applesauce, toast) for diarrhea
• Avoid caffeine, alcohol, and dairy during acute symptoms
• If you cannot keep fluids down for 24 hours, call your provider, risk of dehydration-induced kidney injury

Constipation (24%)

• Increase fiber gradually (25-30g/day), too much too fast worsens GI symptoms
• Drink at least 64oz of water daily, more if active
• Walking 30 minutes daily helps gut motility
• OTC stool softeners (docusate) are safe for short-term use; check with provider before laxatives
• Persistent constipation past 1 week with abdominal distension warrants a provider call

Hair shedding (5.4%)

• This is telogen effluvium, caused by rapid weight loss, not the drug acting on hair follicles directly
• Ensure 60-80g/day of protein intake (this is harder than it sounds when appetite is suppressed)
• Test ferritin (iron storage), vitamin D, and biotin BEFORE supplementing, random supplementation can mask deficiencies
• Regrowth typically begins 3-6 months after weight stabilizes

Serious side effects, recognize these red flags

Rare but serious. Knowing the warning signs is the difference between a manageable problem and an emergency.

Pancreatitis

<0.5% (rare but serious)

Red-flag symptoms: Severe upper abdominal pain radiating to the back, with persistent nausea or vomiting

Action: STOP Foundayo and seek emergency care immediately. Do not restart without provider clearance.

Gallbladder problems

Reported in trials at rates similar to other GLP-1s (1-3%)

Red-flag symptoms: Sharp upper-right abdominal pain after fatty meals, fever, jaundice

Action: Contact your provider for imaging. Rapid weight loss is the primary risk factor.

Acute kidney injury

Rare

Red-flag symptoms: Decreased urine output, swelling, fatigue, usually after persistent vomiting or diarrhea causing dehydration

Action: Maintain aggressive hydration during GI symptoms. If you cannot keep fluids down for 24 hours, contact your provider or ER.

Hypoglycemia

Variable, primarily in patients also taking insulin or sulfonylureas

Red-flag symptoms: Shakiness, sweating, confusion, rapid heartbeat, blurred vision

Action: Treat immediately with 15g fast-acting carbs (juice, glucose tablets). Recheck in 15 minutes. Discuss insulin/sulfonylurea dose reduction with your prescriber if recurring.

Severe allergic reaction (anaphylaxis)

Rare (<0.1%)

Red-flag symptoms: Difficulty breathing, throat or facial swelling, widespread hives, drop in blood pressure

Action: CALL 911. Do not drive yourself.

Suicidal ideation

Under FDA post-marketing review (class-wide, no causal link established)

Red-flag symptoms: New or worsening depression, mood changes, self-harm thoughts

Action: Contact your provider AND report to FDA MedWatch (1-800-FDA-1088). The 988 Suicide & Crisis Lifeline is available 24/7.

The boxed warning: thyroid C-cell tumors

Foundayo carries a boxed warning for thyroid C-cell tumors as a class-wide labeling for GLP-1 receptor agonists. However, one Foundayo-specific data point: orforglipron did not produce thyroid tumors in the rodent studies that led to the boxed warning for injectable GLP-1s like Wegovy and Ozempic. The FDA retained the class-level warning out of regulatory caution, not because of orforglipron-specific findings.

Foundayo is contraindicated in patients with:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Your prescriber should screen for these before initiating Foundayo. If a telehealth provider does not ask about thyroid history during intake, treat that as a quality flag. Programs with stronger clinical oversight catch this systematically.

Choosing a provider for Foundayo

Foundayo became commercially available April 6, 2026. Telehealth platforms that list Foundayo include:

Ro
Shed
Lemonaid Health
Found
Eli Lilly's direct-to-consumer LillyDirect also offers it

A listing is not a safety, compliance, or price certification; program fees can differ from LillyDirect's medication price. The medical-oversight pattern still matters. Programs that include regular check-ins, willingness to hold dose escalation, and labs to catch issues early earn their place during the 16-week titration window.

Compare each program's current clinical-oversight evidence in our full rankings. Overall scores incorporate price, medication options, experience, and transparency as well as oversight; they are not a medical-safety endorsement.

See how all 54 providers score on clinical oversight in the full rankings, or take the 60-second match quiz to find providers that fit your support needs.

Wegovy side effects deep dive , for users comparing oral Foundayo to injectable semaglutide
Zepbound side effects deep dive , tirzepatide for weight loss (higher loss but injectable)
Ozempic side effects deep dive
Foundayo vs Wegovy pill: price and trial-results comparison
Foundayo (orforglipron) guide 2026 , full overview of the new oral GLP-1
Cross-drug GLP-1 side effects comparison

Sources

This page is for informational purposes only and is not medical advice. Always discuss medication decisions with a licensed prescriber. Side-effect rates are population averages from clinical trials and may not reflect your individual experience. If you are experiencing a medical emergency, call 911.